Transfer factor therapy in patients with cancer

Area of Science:

• Immunology
• Oncology
• Cellular Biology

Background:

• Advanced, recurrent cancers often lack effective conventional therapies.
• Cell-mediated immunity plays a crucial role in tumor surveillance and rejection.
• Transfer factor is a cell-free extract containing immune-response modifiers.

Purpose of the Study:

• To investigate the efficacy of transfer factor in stimulating specific cell-mediated immunity against tumor antigens in cancer patients.
• To assess the clinical outcomes of transfer factor immunotherapy in patients with advanced, recurrent cancers.

Main Methods:

• Transfer factor was prepared from cohabitants of 35 selected cancer patients.
• Patients received transfer factor infusions at 2-week intervals.
• Clinical responses and dermal reactivity to tumor antigens were monitored.

Main Results:

• A clinical effect was observed in 13 patients, including tumor regression, arrest of metastasis, and pain relief.
• Conversion of dermal reactivity to tumor antigens correlated with clinical improvement.
• Short duration of clinical benefit (2 weeks to 12 months) was noted.
• Serum blocking of lymphocyte responsiveness was present in non-responding patients.

Conclusions:

• Transfer factor can successfully stimulate specific cell-mediated immunity in cancer patients.
• This immunotherapy can produce a clinical effect on tumors under specific conditions.
• Further research is needed to optimize transfer factor therapy and overcome resistance mechanisms.